Peroxisome proliferator-activated receptor gamma rs1801282 C>G polymorphism is associated with polycystic ovary syndrome susceptibility: a meta-analysis involving 7,069 subjects.

In the peroxisome proliferator-activated receptor gamma (PPARG) gene, a polymorphism (rs1801282 C>G), has been shown to change an amino acid residue and then results in alternation of PPARG function. A number of studies have explored the relationship between PPARG rs1801282 C>G variants and polycystic ovary syndrome (PCOS) risk, but yielding inconsistent findings, especially in Asian population. This study aimed to assess the role of PPARG rs1801282 C>G polymorphism in susceptibility to PCOS. Databases of Pubmed, Embase and China National Knowledge Internet (CNKI) were searched until August 2, 2015. The association of PPARG 1801282 C>G polymorphism with PCOS risk was evaluated by crude odds ratios (ORs) with their 95% confidence intervals (CIs). Finally, there were twenty-three studies involving 3,458 PCOS cases and 3,611 controls included in our pooled analysis. Significant associations were identified between PPARG rs1801282 C>G variants and decreased PCOS risk in three genetic comparison models (OR, 0.78; 95% CI, 0.69-0.89; P < 0.001 for G vs. C; OR, 0.77; 95% CI, 0.68-0.89; P < 0.001 for GG+CG vs. CC and OR, 0.79; 95% CI, 0.68-0.91; P = 0.001 for CG vs. CC). In a subgroup analysis by race, significant correlation was also observed between PPARG rs1801282 C>G variants and decreased PCOS risk in three genetic models: G vs. C (OR, 0.83; 95% CI, 0.71-0.97; P = 0.019) and GG+CG vs. CC (OR, 0.83; 95% CI, 0.70-0.99; P = 0.033) among Caucasians and in one genetic models: G vs. C (OR, 0.72; 95% CI, 0.59-0.88; P = 0.001) among Asians. In summary, our results demonstrate that PPARG rs1801282 C>G polymorphism may be a protective factor for PCOS.